Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy with IVIG, cyclophosphamide and methylprednisolone in paraneoplastic sensory neuronopathy with anti-Hu antibodies
2019-000177-23Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of immune globulin, cyclophosphamide and methylprednisolone in paraneoplastic sensory neuronopathy (PSN) and paraneoplastic neurological syndrome (PNS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical improvement on ONLS at 3 months. Started Apr 2019; status: completed.
02
Drugs
immune globulincyclophosphamidemethylprednisolone
03
Conditions
paraneoplastic sensory neuronopathy (PSN)paraneoplastic neurological syndrome (PNS)
Beyond the preview
Go deeper on 2019-000177-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000177-23.